ResMed Total Revenue vs Ebit Analysis

RMD Stock

USD 213.99 3.20 1.47%

ResMed financial indicator trend analysis is much more than just breaking down ResMed Inc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ResMed Inc is a good investment. Please check the relationship between ResMed Total Revenue and its Ebit accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

Total Revenue vs Ebit

Total Revenue vs Ebit Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ResMed Inc Total Revenue account and Ebit. At this time, the significance of the direction appears to have totally related.

The correlation between ResMed's Total Revenue and Ebit is 0.99. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Ebit in the same time period over historical financial statements of ResMed Inc, assuming nothing else is changed. The correlation between historical values of ResMed's Total Revenue and Ebit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of ResMed Inc are associated (or correlated) with its Ebit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebit has no effect on the direction of Total Revenue i.e., ResMed's Total Revenue and Ebit go up and down completely randomly.

Correlation Coefficient

0.99

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Total Revenue

Total revenue comprises all receipts ResMed Inc generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Ebit

Most indicators from ResMed's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ResMed Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

At present, ResMed's Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 451 M, whereas Issuance Of Capital Stock is forecasted to decline to about 48.2 M.

	2021	2022	2023	2024 (projected)
Gross Profit	2.0B	2.4B	2.7B	2.8B
Total Revenue	3.6B	4.2B	4.9B	5.1B

Gross Profit Total Revenue

ResMed fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Property Plant And Equipment Gross	Common Stock Total Equity	Short Term Investments
Total Assets		0.91	0.81	0.88	0.98	0.93	0.87	0.99	0.96	-0.33	0.98	0.92	-0.32	0.97	0.6	0.94	0.96	0.94	0.65	0.97	0.91	-0.17	0.93	0.93	0.42	0.69
Short Long Term Debt Total	0.91		0.63	0.77	0.84	0.76	0.92	0.86	0.85	-0.28	0.92	0.77	-0.28	0.84	0.48	0.98	0.84	0.78	0.49	0.97	0.78	0.0	0.95	0.76	0.33	0.65
Other Current Liab	0.81	0.63		0.9	0.8	0.78	0.72	0.79	0.82	-0.51	0.85	0.83	-0.51	0.82	0.47	0.68	0.74	0.74	0.63	0.78	0.61	-0.36	0.8	0.78	0.35	0.72
Total Current Liabilities	0.88	0.77	0.9		0.85	0.86	0.74	0.87	0.88	-0.27	0.87	0.8	-0.27	0.89	0.63	0.75	0.78	0.77	0.5	0.86	0.76	0.04	0.83	0.86	0.5	0.6
Total Stockholder Equity	0.98	0.84	0.8	0.85		0.96	0.79	0.99	0.94	-0.28	0.95	0.91	-0.28	0.97	0.62	0.87	0.97	0.97	0.69	0.91	0.94	-0.19	0.86	0.96	0.43	0.64
Property Plant And Equipment Net	0.93	0.76	0.78	0.86	0.96		0.65	0.94	0.93	-0.07	0.87	0.79	-0.07	0.94	0.77	0.78	0.88	0.89	0.59	0.84	0.96	-0.12	0.77	1.0	0.59	0.52
Net Debt	0.87	0.92	0.72	0.74	0.79	0.65		0.82	0.8	-0.62	0.93	0.86	-0.62	0.8	0.25	0.95	0.84	0.78	0.61	0.94	0.62	-0.23	0.97	0.65	0.12	0.82
Retained Earnings	0.99	0.86	0.79	0.87	0.99	0.94	0.82		0.97	-0.3	0.96	0.92	-0.29	0.98	0.64	0.9	0.96	0.95	0.61	0.94	0.92	-0.15	0.89	0.94	0.46	0.63
Accounts Payable	0.96	0.85	0.82	0.88	0.94	0.93	0.8	0.97		-0.28	0.94	0.86	-0.28	0.96	0.67	0.88	0.89	0.87	0.52	0.93	0.87	-0.18	0.89	0.93	0.53	0.66
Cash	-0.33	-0.28	-0.51	-0.27	-0.28	-0.07	-0.62	-0.3	-0.28		-0.47	-0.57	1.0	-0.28	0.34	-0.38	-0.4	-0.35	-0.52	-0.37	0.06	0.59	-0.49	-0.07	0.36	-0.72
Non Current Assets Total	0.98	0.92	0.85	0.87	0.95	0.87	0.93	0.96	0.94	-0.47		0.94	-0.47	0.95	0.51	0.95	0.94	0.91	0.67	0.98	0.82	-0.24	0.97	0.87	0.34	0.76
Non Currrent Assets Other	0.92	0.77	0.83	0.8	0.91	0.79	0.86	0.92	0.86	-0.57	0.94		-0.57	0.91	0.44	0.85	0.91	0.89	0.66	0.88	0.74	-0.32	0.88	0.79	0.27	0.67
Cash And Short Term Investments	-0.32	-0.28	-0.51	-0.27	-0.28	-0.07	-0.62	-0.29	-0.28	1.0	-0.47	-0.57		-0.27	0.34	-0.38	-0.4	-0.35	-0.52	-0.37	0.06	0.59	-0.49	-0.07	0.36	-0.72
Net Receivables	0.97	0.84	0.82	0.89	0.97	0.94	0.8	0.98	0.96	-0.28	0.95	0.91	-0.27		0.7	0.88	0.91	0.9	0.54	0.93	0.9	-0.15	0.89	0.94	0.53	0.6
Common Stock Shares Outstanding	0.6	0.48	0.47	0.63	0.62	0.77	0.25	0.64	0.67	0.34	0.51	0.44	0.34	0.7		0.46	0.46	0.47	0.06	0.53	0.73	0.14	0.45	0.77	0.94	0.08
Non Current Liabilities Total	0.94	0.98	0.68	0.75	0.87	0.78	0.95	0.9	0.88	-0.38	0.95	0.85	-0.38	0.88	0.46		0.88	0.83	0.55	0.98	0.78	-0.17	0.97	0.78	0.31	0.71
Inventory	0.96	0.84	0.74	0.78	0.97	0.88	0.84	0.96	0.89	-0.4	0.94	0.91	-0.4	0.91	0.46	0.88		0.99	0.77	0.9	0.89	-0.24	0.86	0.88	0.26	0.7
Other Current Assets	0.94	0.78	0.74	0.77	0.97	0.89	0.78	0.95	0.87	-0.35	0.91	0.89	-0.35	0.9	0.47	0.83	0.99		0.77	0.86	0.9	-0.23	0.8	0.9	0.27	0.67
Other Stockholder Equity	0.65	0.49	0.63	0.5	0.69	0.59	0.61	0.61	0.52	-0.52	0.67	0.66	-0.52	0.54	0.06	0.55	0.77	0.77		0.57	0.54	-0.45	0.56	0.59	-0.11	0.75
Total Liab	0.97	0.97	0.78	0.86	0.91	0.84	0.94	0.94	0.93	-0.37	0.98	0.88	-0.37	0.93	0.53	0.98	0.9	0.86	0.57		0.82	-0.12	0.99	0.84	0.38	0.72
Total Current Assets	0.91	0.78	0.61	0.76	0.94	0.96	0.62	0.92	0.87	0.06	0.82	0.74	0.06	0.9	0.73	0.78	0.89	0.9	0.54	0.82		0.03	0.72	0.96	0.54	0.41
Short Term Debt	-0.17	0.0	-0.36	0.04	-0.19	-0.12	-0.23	-0.15	-0.18	0.59	-0.24	-0.32	0.59	-0.15	0.14	-0.17	-0.24	-0.23	-0.45	-0.12	0.03		-0.2	-0.12	0.16	-0.49
Intangible Assets	0.93	0.95	0.8	0.83	0.86	0.77	0.97	0.89	0.89	-0.49	0.97	0.88	-0.49	0.89	0.45	0.97	0.86	0.8	0.56	0.99	0.72	-0.2		0.77	0.31	0.77
Property Plant And Equipment Gross	0.93	0.76	0.78	0.86	0.96	1.0	0.65	0.94	0.93	-0.07	0.87	0.79	-0.07	0.94	0.77	0.78	0.88	0.9	0.59	0.84	0.96	-0.12	0.77		0.59	0.53
Common Stock Total Equity	0.42	0.33	0.35	0.5	0.43	0.59	0.12	0.46	0.53	0.36	0.34	0.27	0.36	0.53	0.94	0.31	0.26	0.27	-0.11	0.38	0.54	0.16	0.31	0.59		0.04
Short Term Investments	0.69	0.65	0.72	0.6	0.64	0.52	0.82	0.63	0.66	-0.72	0.76	0.67	-0.72	0.6	0.08	0.71	0.7	0.67	0.75	0.72	0.41	-0.49	0.77	0.53	0.04

Click cells to compare fundamentals

ResMed Account Relationship Matchups

ResMed fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	4.6B	4.7B	5.1B	6.8B	7.8B	8.2B
Short Long Term Debt Total	1.3B	793.7M	917.6M	1.6B	1.8B	1.9B
Other Current Liab	335.1M	628.6M	389.6M	437.9M	503.6M	528.7M
Total Current Liabilities	602.8M	911.8M	689.3M	758.5M	872.3M	915.9M
Total Stockholder Equity	2.5B	2.9B	3.4B	4.1B	4.7B	5.0B
Property Plant And Equipment Net	535.7M	592.1M	630.5M	665.8M	765.7M	804.0M
Net Debt	836.1M	498.4M	643.8M	1.4B	1.6B	1.6B
Retained Earnings	2.8B	3.1B	3.6B	4.3B	4.9B	5.1B
Accounts Payable	135.8M	138.0M	159.2M	150.8M	173.4M	182.0M
Cash	463.2M	295.3M	273.7M	227.9M	262.1M	335.8M
Non Current Assets Total	3.1B	3.2B	3.2B	4.4B	5.0B	5.3B
Non Currrent Assets Other	189.7M	240.8M	251.5M	395.4M	454.7M	477.5M
Cash And Short Term Investments	463.2M	295.3M	273.7M	227.9M	262.1M	340.4M
Net Receivables	474.6M	614.3M	576.0M	704.9M	810.6M	851.2M
Common Stock Shares Outstanding	145.7M	146.5M	147.0M	147.5M	169.6M	147.3M
Liabilities And Stockholders Equity	4.6B	4.7B	5.1B	6.8B	7.8B	8.2B
Non Current Liabilities Total	1.5B	930.7M	1.0B	1.9B	2.1B	2.2B
Inventory	416.9M	457.0M	743.9M	998.0M	1.1B	1.2B
Other Current Assets	168.7M	208.2M	337.9M	437.0M	502.6M	527.7M
Other Stockholder Equity	(52.6M)	(1.1M)	59.2M	148.8M	133.9M	140.6M
Total Liab	2.1B	1.8B	1.7B	2.6B	3.0B	3.2B
Total Current Assets	1.5B	1.6B	1.9B	2.4B	2.7B	2.9B
Short Term Debt	33.3M	35.6M	31.8M	31.8M	36.6M	66.7M
Intangible Assets	448.2M	392.6M	345.9M	552.3M	635.2M	667.0M
Property Plant And Equipment Gross	535.7M	592.1M	630.5M	665.8M	765.7M	804.0M
Accumulated Other Comprehensive Income	(284.0M)	(193.5M)	(312.7M)	(272.5M)	(245.3M)	(233.0M)
Common Stock Total Equity	571K	575K	580K	583K	670.5K	417.0K
Common Stock	580K	583K	586K	588K	676.2K	435.6K
Other Assets	145.6M	240.8M	202.3M	261.3M	300.5M	315.5M
Good Will	1.9B	1.9B	1.9B	2.8B	3.2B	3.3B
Property Plant Equipment	535.7M	592.1M	630.5M	665.8M	765.7M	384.1M
Other Liab	221.6M	172.6M	160.0M	315.2M	362.5M	380.6M
Long Term Debt	1.2B	643.4M	765.3M	1.4B	1.6B	1.7B
Current Deferred Revenue	98.6M	109.6M	108.7M	138.1M	158.8M	166.7M
Net Tangible Assets	158.5M	565.2M	1.1B	807.3M	726.5M	632.7M
Long Term Debt Total	1.3B	1.2B	643.4M	765.3M	880.1M	737.7M
Capital Surpluse	1.5B	1.6B	1.6B	1.7B	1.9B	1.5B

Currently Active Assets on Macroaxis

F	Ford Motor
GOOG	Alphabet Inc Class C
MSFT	Microsoft
GOOG	Alphabet Inc Class C
F	Ford Motor

When determining whether ResMed Inc is a strong investment it is important to analyze ResMed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ResMed's future performance. For an informed investment choice regarding ResMed Stock, refer to the following important reports:

How To Invest In ResMed

Details

Is ResMed Stock a good investment?

Details

What is ResMed's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for ResMed Stock analysis

When running ResMed's price analysis, check to measure ResMed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ResMed is operating at the current time. Most of ResMed's value examination focuses on studying past and present price action to predict the probability of ResMed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ResMed's price. Additionally, you may evaluate how the addition of ResMed to your portfolios can decrease your overall portfolio volatility.

	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals

Is ResMed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ResMed. If investors know ResMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ResMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.291

Dividend Share

1.88

Earnings Share

6.49

Revenue Per Share

31.175

Quarterly Revenue Growth

0.072

The market value of ResMed Inc is measured differently than its book value, which is the value of ResMed that is recorded on the company's balance sheet. Investors also form their own opinion of ResMed's value that differs from its market value or its book value, called intrinsic value, which is ResMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ResMed's market value can be influenced by many factors that don't directly affect ResMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ResMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if ResMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ResMed Total Revenue vs Ebit Analysis

Total Revenue vs Ebit

Total Revenue vs Ebit Correlation Analysis

Correlation Coefficient

Total Revenue

Ebit

ResMed fundamental ratios Correlations

ResMed Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ResMed fundamental ratios Accounts

Currently Active Assets on Macroaxis

Complementary Tools for ResMed Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Retained Earnings	+ 0.99	Total Assets
Retained Earnings	+ 0.99	Total Stockholder Equity
Other Current Assets	+ 0.99	Inventory
Intangible Assets	+ 0.99	Total Liab

Short Term Investments	- 0.72	Cash And Short Term Investments
Short Term Investments	- 0.72	Cash
Cash And Short Term Investments	- 0.62	Net Debt
Cash	- 0.62	Net Debt
Cash And Short Term Investments	- 0.57	Non Currrent Assets Other
Non Currrent Assets Other	- 0.57	Cash